Carisma Therapeutics Statistics
Want to see CARM full AI Analyst Report?
Carisma Therapeutics (CARM) Stock Statistics & Valuation Metrics
Total Valuation
Carisma Therapeutics has a market cap or net worth of $8,369.00. The enterprise value is -$1.18T.
- Market Cap
- $8,369.00
- Enterprise Value
- -$1.18T
Share Statistics
Carisma Therapeutics has 41,845,078 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 41,845,078
- Owned by Insiders
- ―
- Owned by Institutions
- 0.26%
Financial Efficiency
Carisma Therapeutics’s return on equity (ROE) is 2.17 and return on invested capital (ROIC) is -385.25%.
- Return on Equity (ROE)
- 2.17
- Return on Assets (ROA)
- -1.99
- Return on Invested Capital (ROIC)
- -385.25%
- Return on Capital Employed (ROCE)
- -4.32
- Revenue Per Employee
- 426.78K
- Profits Per Employee
- -1.31M
- Employee Count
- 46
- Asset Turnover
- 0.64
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Carisma Therapeutics is 0.00. Carisma Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- 0.00
- PS Ratio
- 0.00
- PB Ratio
- -0.01
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Carisma Therapeutics had revenue of 19.63M and earned -60.48M in profits. Earnings per share was -1.46.
- Revenue
- 19.63M
- Gross Profit
- -40.04M
- Operating Income
- -62.18M
- Pretax Income
- -60.48M
- Net Income
- -60.48M
- EBITDA
- -56.83M
- Earnings Per Share (EPS)
- -1.46
Cash Flow
In the last 12 months, operating cash flow was -22.41M and capital expenditures 0, giving a free cash flow of -22.41M billion.
- Operating Cash Flow
- -22.41M
- Free Cash Flow
- -22.41M
- Free Cash Flow per Share
- -0.10
Dividends & Yields
Carisma Therapeutics pays an annual dividend of $0.36, resulting in a dividend yield of ―
- Dividend Per Share
- $0.36
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -47747.64%
- Earnings Yield
- 418097.54%
Stock Price Statistics
- Beta
- 8.07
- 52-Week Price Change
- -42.86%
- 50-Day Moving Average
- 0.03
- 200-Day Moving Average
- 0.04
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 1,220
Important Dates
Carisma Therapeutics upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Nov 06, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- Mar 08, 2023
Financial Position
Carisma Therapeutics as a current ratio of 1.48, with Debt / Equity ratio of -8.89%
- Current Ratio
- 1.48
- Quick Ratio
- 1.48
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.27
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Carisma Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Carisma Therapeutics EV to EBITDA ratio is -0.05, with an EV/FCF ratio of 0.50.
- EV to Sales
- -0.04
- EV to EBITDA
- -0.05
- EV to Free Cash Flow
- 0.50
- EV to Operating Cash Flow
- 0.50
Balance Sheet
Carisma Therapeutics has $2.78M in cash and marketable securities with $762.00K in debt, giving a net cash position of $2.02M billion.
- Cash & Marketable Securities
- $2.78M
- Total Debt
- $762.00K
- Net Cash
- $2.02M
- Net Cash Per Share
- $0.05
- Tangible Book Value Per Share
- -$0.02
Margins
Gross margin is 99.21%, with operating margin of 84.06%, and net profit margin of 77.22%.
- Gross Margin
- 99.21%
- Operating Margin
- 84.06%
- Pretax Margin
- 77.22%
- Net Profit Margin
- 77.22%
- EBITDA Margin
- 86.84%
- EBIT Margin
- 86.05%
Scores
- Smart Score
- ―
- AI Score
- 40

